Abhinav Deol

Position Title

Associate Professor - Clinical
Hematology-Oncology

Office Location

Karmanos Cancer Institute
4100 John R.
Hudson-Webber Cancer Research Center
Mail Code: HW04HO
Detroit, MI 48201

Office Phone

(313) 576-8093

Office Fax

(313) 576-8766

Education Training

Education
(1999)  MBBS, Government Medical College, Amritsar, Punjab, India

Postgraduate Training
(2007-2010)  Hematology Oncology Fellow, Barbara Ann Karmanos Cancer Institute/Wayne State University School of Medicine. Detroit, MI
(2004-2007)  Resident, Department of Internal Medicine, Wayne State University School of Medicine/Detroit Medical Center. Detroit, MI

Professional Experience

Faculty Appointments

(2016-Present)  Associate Professor - Clinical, Department of Oncology, Division of Hematology-Oncology, Wayne State University School of Medicine, Detroit, MI
(2010-2016)  Assistant Professor of Oncology, Division of Hematology & Oncology, Department of Oncology, Wayne State University School of Medicine, Detroit, MI

Hospital or Other Professional Appointments
(2012-Present)  Member, Medical Executive Committee, Karmanos Cancer Institute
(2011-Present)  Co-Physician Leader, Electronic Medical Records Project, Karmanos Cancer Center
(2011-Present)  Member, Credentialing Committee, Karmanos Cancer Center
(2010-Present)  Clinical Member, Developmental Therapeutics Program, Karmanos Cancer Center
(2010-Present)  Physician, Oncology Department, Karmanos Cancer Center.  Detroit, MI
(2010-Present)  Chair, Computerized Physician Order Entry (CPOE) Committee, Karmanos Cancer Center.  Detroit, MI
(2011-2012) Member, Electronic Medical Records (EMR) Steering Committee, Karmanos Cancer Center, Detroit, MI
(2003)  Instructor, Department of Physiology, Government Medical College.  Chandigarh, India
(2002)  Medical Officer, Arora Neuro Center. Ludhiana, India
(2001)  Junior Resident, Department of Surgery, Government Medical College, Chandigarh, India
(2000)  Medical Officer, Detoxification and Rehabilitation Center, Guru Nanak Mission Charitable Trust, Ludhiana, India

Major Professional Societies

American Society of Clinical Oncology
American Society of Hematology
American Society of Blood and Marrow Transplantation

Board Certification

American Board of Internal Medicine
American Board of Internal Medicine, Subspecialty Certification in Medical Oncology
American Board of Internal Medicine, Subspecialty in Hematology

Honors and Awards

(2016) Hematology-Oncology Fellowship Program Teaching Award, Wayne State University, Karmanos Cancer Institute, Detroit, MI
(2015) School of Medicine College Teaching Award, Department of Oncology, Wayne State University, Detroit, MI
(2015) Hematology-Oncology Fellowship Program Teaching Award, Wayne State University, Karmanos Cancer Institute, Detroit, MI
(2011) American Society of Blood and Marrow Transplant, Clinical Research Training Course, Santa Fe, NM
(2009) American Society of Hematology Travel Grant, ASH Annual Meeting
(2006) Award for Excellence in Geriatrics. Detroit Receiving Hospital. Detroit, MI
(2005-2006) Resident of the Year Award. Harper University Hospital. Detroit, MI
(2004) Honorable Mention. First Annual AMA-RFS Meeting. Atlanta, GA
(2004) Intern of the Month, Detroit Receiving Hospital. Detroit, MI

 

Courses taught

6400 Pathophysiology – Hematology Section
Medical Resident Instruction

Research Interests

Hematopoietic Stem Cell Transplant
Acute/ Chronic Leukemia, Lymphomas

Publications

Bhutani D, Zonder J, Valent J, Tageja N, Ayash L, Deol A, Al-Kadhimi Z, Abrams J, Lum L, Ratanatharathorn V, Uberti J, Abidi MH. Evaluating the effects of lenalidomide induction therapy on peripheral stem cells collection in patients undergoing autologous stem cell transplant for multiple myeloma. Support Care Cancer. 2013 Apr 17. [Epub ahead of print]

Lum LG, Thakur A, Liu Q, Deol A, Al-Kadhimi Z, Ayash L, Abidi MH, Pray C, Tomaszewski EN, Steele PA, Schalk DL, Yano H, Mitchell A, Dufresne M, Uberti JP, Ratanatharathorn V. CD20-targeted T cells after stem cell transplantation for high risk and refractory non-Hodgkin's lymphoma. Biol Blood Marrow Transplant. 2013 Jun;19(6):925-33. doi: 10.1016/j.bbmt.2013.03.010. Epub 2013 Mar 22.

Deol A, Abrams J, Masood A, Al-Kadhimi Z, Abidi MH, Ayash L, Lum LG, Ratanatharathorn V, Uberti JP. Long-Term Follow Up of Patients Proceeding to Transplant Using Plerixafor Mobilized Stem Cells and Incidence of Secondary Acute Myeloid Leukemia / Myelodysplastic Syndrome. Bone Marrow Transplant. 2013 Mar 11. doi: 10.1038/bmt.2013.10. [Epub ahead of print]

Al-Kadhimi Z, Gul Z, Rodriguez R, Chen W, Smith D, Mitchell A, Abidi M, Ayash L, Deol A, Lum L, Forman S, Ratanatharathorn V, Uberti J. Anti-Thymocyte Globulin (Thymoglobulin), Tacrolimus, and Sirolimus as Acute Graft-versus-Host Disease Prophylaxis for Unrelated Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2012 Jun 16. [Epub ahead of print]

Abidi MH, Gul Z, Abrams J, Ayash L, Deol A, Ventimiglia M, Lum L, Mellon-Reppen S, Al-Kadhimi Z, Ratanatharathorn V, Zonder J, Uberti J. Phase I trial of bortezomib during maintenance phase after high dose melphalan and autologous stem cell transplantation in patients with multiple myeloma. J Chemother. 2012; 24(3):167-72.

Abidi MH, Agarwal R, Ayash L, Deol A, Al-Kadhimi Z, Abrams J, Cronin S, Ventimiglia M, Lum L, Ratanatharathorn V, Uberti J. Melphalan 180 mg/m(2) can be Safely Administered as Conditioning Regimen prior to an Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma Patients with Creatinine Clearance 60 mL/min/1.73 m(2) or lower with use of palifermin for Cytoprotection: Results of a Phase I Trial. Biol Blood Marrow Transplant. 2012 Mar 24. [Epub ahead of print]

Warlick E, Ahn KW, Pedersen TL, Artz A, de Lima M, Pulsipher M, Akpek G, Aljurf M, Cahn JY, Cairo M, Chen YB, Cooper B, Deol A, Giralt S, Gupta V, Khoury HJ, Kohrt H, Lazarus HM, Lewis I, Olsson R, Pidala J, Savani B, Seftel M, Socié G, Tallman M, Ustun C, Vij R, Vindeløv L, Weisdorf D. RIC is superior to NMA conditioning for older Chronic Myelogenous Leukemia patients undergoing Hematopoietic Cell Transplant during the TKI Era. Blood. 2012 Mar 9. [Epub ahead of print]

Lum LG, Ramesh M, Thakur A, Mitra S, Deol A, Uberti JP, Pellett PE.Targeting Cytomegalovirus-Infected Cells Using T Cells Armed with Anti-CD3 × Anti-CMV Bispecific Antibody. Biol Blood Marrow Transplant. 2012 Feb 5. [Epub ahead of print]

Deol A, Ratantharathorn V, Uberti JP; Pathophysiology, Prevention and Treatment of Acute Graft-vs-Host Disease; Transplant Research and Risk Management 2011, 3:31-44, 07 March 2011

Deol A, Lum LG. Role of Donor Lymphocyte Infusion in Relapsed Hematological Malignancies after stem cell transplantation revisited; Cancer Treat Rev. Nov 2010 36(7), 528-38

Faculty Status

Hem-Onc

← Return to listing